ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Roche Holdings Ltd AG (QX)

Roche Holdings Ltd AG (QX) (RHHBY)

35.13
-0.28
(-0.79%)
Closed 21 November 8:00AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
35.13
Bid
35.04
Offer
35.42
Volume
1,111,491
35.03 Day's Range 35.38
29.20 52 Week Range 42.43
Market Cap
Previous Close
35.41
Open
35.34
Last Trade
27
@
35.15
Last Trade Time
Financial Volume
US$ 39,077,403
VWAP
35.1576
Average Volume (3m)
1,358,162
Shares Outstanding
6,389,213,336
Dividend Yield
3.84%
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
58.72B
Net Profit
11.5B

About Roche Holdings Ltd AG (QX)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Basel, Che
Founded
-
Roche Holdings Ltd AG (QX) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker RHHBY. The last closing price for Roche (QX) was US$35.41. Over the last year, Roche (QX) shares have traded in a share price range of US$ 29.20 to US$ 42.43.

Roche (QX) currently has 6,389,213,336 shares in issue. The market capitalisation of Roche (QX) is US$226.24 billion.

RHHBY Latest News

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving cancer therapies has never been more critical. With millions of lives and billions of To read the full...

Roche's Cancer Injection Tecentriq SC Gets European Commission Approval

By Andrea Figueras Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple cancer types. The Swiss pharmaceutical company said...

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

  January 10, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved...

LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche

By Stephen Nakrosis LumiraDx said Friday it will sell certain companies related to its point-of-care technology to Roche. Andrew Johnson, Lisa Rickelton and Lindsay Hallam of FTI Consulting, who...

Roche's Xolair Granted FDA Priority Review

By Mauro Orru Roche Holding's Xolair antibody received priority review treatment from the Food and Drug Administration after a late-stage study yielded positive results that the company said...

Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment

By Sabela Ojea Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial for a blood cancer treatment. At 9:43 a.m. ET...

Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment

By Andrea Figueras Roche said that it has received positive long-term follow-up data and significant overall survival benefit from the Katherine study, which examines people with early-stage...

Roche's Inavolisib Breast Cancer Drug Gets Positive Results

By Andrea Figueras Roche said it obtained positive results for its investigational treatment, inavolisib, as a first-line treatment for people with breast cancer. The drug, which combines...

Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials

By Helena Smolak Shares of Germany's Merck KGaA plunged after its experimental drug evobrutinib failed in two late-stage trials of patients with relapsing forms of multiple sclerosis. At 0927...

Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study

By Mauro Orru Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer. The Swiss pharmaceutical company said Tuesday...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.08-5.5898951894737.2137.2735.03103137535.98069641DR
4-4.76-11.932815241939.8940.6735.03115966038.59951372DR
12-6.65-15.916706558241.7842.4335.03135816239.0973737DR
262.136.454545454553342.4331.19173371737.13131885DR
521.765.2741983817833.3742.4329.2207514534.52768357DR
156-14.28-28.901032179749.4153.8627.95185174038.249473DR
260-3-7.8678206136938.1353.8627.95173988239.98221416DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EGRNFChina Evergrande Group (CE)
US$ 0.0102
(1,019,900.00%)
900
WRCDFWirecard AG (CE)
US$ 0.01
(999,900.00%)
350
CCTLCoin Citadel (PK)
US$ 0.0002
(19,900.00%)
1.28M
RDVARDVA Inc (CE)
US$ 0.0002
(19,900.00%)
10k
AGRDFMinnova Corporation (PK)
US$ 0.0101
(10,000.00%)
10k
ISUNQiSun Inc (CE)
US$ 0.000001
(-99.86%)
12.5k
YAYOYayYo Inc (CE)
US$ 0.000001
(-99.80%)
44.61k
GBCHFMetaverse Capital Corporation (CE)
US$ 0.000001
(-99.00%)
200
NTRRNeutra Corporation (CE)
US$ 0.000001
(-99.00%)
40k
BTTXBetter Therapeutics Inc (CE)
US$ 0.000001
(-99.00%)
60.2k
THBDThird Bench Inc (PK)
US$ 0.0001
(0.00%)
183.32M
RDARRaadr Inc (PK)
US$ 0.0006
(-25.00%)
131.72M
BDPTBioadaptives Inc (PK)
US$ 0.0001
(-50.00%)
121.82M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(0.00%)
111.8M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.003
(-14.29%)
97.54M

RHHBY Discussion

View Posts
mick mick 4 weeks ago
๐Ÿ‘๏ธ0
mick mick 2 months ago
$RHHBY

https://www.stockscores.com/charts/charts/?ticker=RHHBY
๐Ÿ‘๏ธ0
mick mick 2 months ago
RHHBY
Roche Holdings Ltd AG (QX)
40.49
-0.15 (-0.37%)
Volume: 1,645,514
Day Range: 40.37 - 41.02
Last Trade Time: 4:05:41 PM EDT
๐Ÿ‘๏ธ0
Hitman970 Hitman970 3 months ago
RHHBY Bull Flag
๐Ÿ‘๏ธ0
mick mick 4 months ago
RHHBY
Roche Holdings Ltd AG (QX)
39.36
0.36 (0.92%)
Volume: 1,748,892
Day Range: 39.03 - 39.44
Last Trade Time: 2:21:03 PM EDT
๐Ÿ‘๏ธ0
north40000 north40000 5 months ago
Roche reported today that its Phase 2-3 Skyscraper-06 trial of Tiragolumab + Tecentriq + chemotherapy failed to meet the primary endpoints, OS and PFS, in NSCLC.

Further, the Tecentriq arm actually reduced OS and PFS when assessed against the comparator arm of pembrolizumab + chemotherapy in the intent to treat population.

The trial will be halted.
๐Ÿ‘๏ธ0
mick mick 6 months ago
RHHBY
Roche Holdings Ltd AG (QX)
31.6525
0.3225 (1.03%)
Volume: 2,731,889
Day Range: 31.36 - 31.66
Last Trade Time: 12:12:50 PM EDT
๐Ÿ‘๏ธ0
avxl_going_long avxl_going_long 6 months ago
https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm
๐Ÿ‘๏ธ0
mick mick 7 months ago
https://www.otcmarkets.com/stock
๐Ÿ‘๏ธ0
mick mick 7 months ago
https://www.otcmarkets.com/stock/RHHBY
๐Ÿ‘๏ธ0
mick mick 7 months ago
https://www.otcmarkets.com/stock/RHHBY/quote
๐Ÿ‘๏ธ0
mick mick 7 months ago
RHHBY - Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
๐Ÿ‘๏ธ0
mick mick 7 months ago
RHHBY
Roche Holdings Ltd AG (QX)
30.55
-0.11 (-0.36%)
Volume: 1,590,266
Day Range: 30.4175 - 30.72
Last Trade Time: 3:11:10 PM EDT
๐Ÿ‘๏ธ0
OptimusPrime555 OptimusPrime555 2 years ago
$25 coming soon!!!
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $40.45 v -0.2 (-0.49%)
Volume: 2,392,479 @03/26/21 4:02:41 PM EDT
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $40.59 v -0.97 (-2.33%)
Volume: 1,535,564 @02/25/21 4:41:58 PM EST
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
42.17 ? -0.67 (-1.56%)
Volume: 719,412 @02/19/21 4:01:33 PM EST
Bid Ask Day's Range
42.15 42.39 42.14 - 42.595
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $42.955 v -0.745 (-1.70%)
Volume: 2,412,777 @02/05/21 4:44:29 PM EST
๐Ÿ‘๏ธ0
mick mick 4 years ago
https://otcbb.swingtradebot.com/equities/RHHBY

N.Y. , NASDAQ
https://swingtradebot.com/equities/RHHBY
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $44.56 ^ 0.61 (1.39%)
Volume: 2,197,266 @01/15/21 4:00:45 PM EST
๐Ÿ‘๏ธ0
mick mick 4 years ago
https://pennystocks.news/otc/?symbol=RHHBY
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $43.97 ^ 0.31 (0.71%)
Volume: 4,429,511 @12/18/20 7:00:39 PM EST
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
42.69 ? 0.01 (0.02%)
Volume: 214,905 @12/07/20 11:52:43 AM EST
Bid Ask Day's Range
42.69 42.79 42.58 - 42.85
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $41.22 v -0.46 (-1.10%)
Volume: 1,491,871 @11/23/20 4:02:03 PM EST
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $41.48 v -0.54 (-1.29%)
Volume: 1,281,222 @11/10/20 4:42:22 PM EST
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $39.99 v -0.21 (-0.52%)
Volume: 1,180,392 @10/30/20 4:04:06 PM EDT
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
41.03 ? 0.08 (0.20%)
Volume: 1,633,263 @10/23/20 4:42:11 PM EDT
Bid Ask Day's Range
41.03 41.17 40.81 - 41.21
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhbby $43.27 ^ 0.44 (1.03%)
Volume: 809,396 @10/02/20 4:42:01 PM EDT
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
44.86 ? 0.14 (0.31%)
Volume: 619,793 @09/25/20 4:41:33 PM EDT
Bid Ask Day's Range
44.8 44.86 44.28 - 44.87
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
whytestocks whytestocks 4 years ago
Breaking News: $RHHBY Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

— Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy — — Final over...

Got this from RHHBY - Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
46.36 ? 0.0 (0.00%)
Volume: 0 @-
Bid Ask Day's Range
46.09 46.65 - - -
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
43.78 ? -0.03 (-0.07%)
Volume: 882,365 @09/04/20 4:42:29 PM EDT
Bid Ask Day's Range
43.78 43.95 42.93 - 44.0
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $43.78 v -0.03 (-0.07%)
Volume: 882,365 @09/04/20 4:42:29 PM EDT
๐Ÿ‘๏ธ0
Nfixus Nfixus 4 years ago
New article including Roche

Why major pharmaceutical and biotech companies will keep growing for years

https://pennystocks.news/why-major-pharmaceutical-and-biotech-companies-will-keep-growing-for-years-gild/
๐Ÿ‘๏ธ0
pennypauly pennypauly 4 years ago
Hey mick if you like RHHBY then you will love VSQTF!! COVID FDA APPROVAL TODAY!

5 to 15 minute blood test please read

August 25, 2020 03:01 ET | Source: Victory Square Technologies Inc.
Victory Square Health received US FDA permission to commence marketing, sales and distribution under EUA
Safetest Covid-19โ„ข test can confirm whether youโ€™re currently infected with the virus causing Covid-19 or whether you were infected before and didnโ€™t know it
VANCOUVER, British Columbia, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc. (โ€œVS Healthโ€ or the "Company") โ€“ a portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) announced today that it was granted permission by the Food & Drug Administration (FDA) in the United States to commence marketing, sales and distribution under the emergency use authorization (EUA) for its Safetest Covid-19 assay for detecting the virus causing Covid-19. Safetest Covid-19 IgG /IgM has demonstrated to the U.S. FDA 93.5% sensitivity and 98.7% specificity.

With 22,977,399 confirmed cases and 800,321 deaths as of August 22nd, 2020, according to the European Centre for Disease Control, the economic damage from Sars-Cov-19 has been deep and widespread. In addition to obtaining greater insights into SARS-CoV19, and accelerating the development of vaccines, better, faster, and less expensive testing is one of the key requirements to successfully and safely opening the economy and getting 2,000,000 post secondary school students in Canada and 16.6 American undergraduates back to school.

"Our mission is to help the global community by delivering the best tests in the market," said Felipe Peixoto, CEO of Victory Square Health. "Testing is one of the most important actions in the push to get back to the normalcy. Safetest Covid-19 is our contribution to this challenge."

The antibody data provided by the Safetest Covid-19 IgM/IgG Elisa test kit covers both immunoglobulins type M (IgM) and G (IgG). When IgM antibodies are present, they can indicate that a patient has an active or recent infection with SARS-CoV-2. When IgG antibodies are present, it indicates a past infection and exposure.

The FDA has been working with manufacturers to accelerate new testing options that improve detection and diagnosis Covid-19 with the EAU program. The result is special exemptions and an accelerated permission process for reliable and validated technology that is accompanied by data. The EAU process by the FDA provides the green light for Victory Square Health to manufacture, market and provide Safetest Covid-19 Elisa kits to high complexity labs in the United States. Based on the strength of test results, Victory Square Health will be submitting an application to EU-CE. Victory Square Health is anticipating permission from ANVISA Brazil from a previously submitted application.

โ€œBased on our outreach and discussions, the demand for this type of test from distributors around the world is high,โ€ said Victory Square Health CEO Peixoto. โ€œVictory Square Health will be providing assistance to as many nations as possible through these distribution channels.โ€

Elisa like Safetest Covid-19 antibody test results are crucial for developing a clear understanding of immunity thresholds and characteristics of infected individuals. High sensitivity antibody tests provide detailed profiles of populations and individuals. This information helps to accelerate the development of vaccines and provides crucial insight into natural immunity and potential thresholds, if they exist. This information will get people back to work, school and normalcy faster and safer.

โ€œWeโ€™re looking forward to working with these important agencies and health practitioners using Safetest Covid-19,โ€ said Shafin Diamond Tejani, CEO of Victory Square. โ€œThe test has demonstrated excellent reliability through valid data, and weโ€™re energized by the opportunity to contribute to Canadaโ€™s domestic and international fight against the pandemic.โ€

The Safetest Covid-19 IgM / IgG Elisa test kits will be produced and available to labs all over the United States in the next few weeks.

Victory Square Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patientโ€™s care and improve health outcomes.
๐Ÿ‘๏ธ0
MustBeTheTruth MustBeTheTruth 4 years ago
A Perfect Storm for Psychedelics Investors
The 2020 Upside

https://www.thecannabisinvestor.ca/the-2020-upside-a-perfect-storm-for-psychedelics-investors/
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
42.55 ? -0.66 (-1.53%)
Volume: 681,342 @08/14/20 4:42:02 PM EDT
Bid Ask Day's Range
42.54 42.56 42.45 - 42.85
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhbby $43.1 v -1.29 (-2.91%)
Volume: 580,390 @07/31/20 4:41:51 PM EDT
๐Ÿ‘๏ธ0
mick mick 4 years ago
$RHHBY Roche Holdings Ltd A (RHHBY)
42.95 ? -1.08 (-2.45%)
Volume: 1,345,422 @07/24/20 4:42:45 PM EDT
Bid Ask Day's Range
42.95 43.12 42.71 - 43.29
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $45.48 ^ 0.55 (1.22%)
Volume: 1,445,071 @07/17/20 4:42:52 PM EDT
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhbby $44.12 ? 0.51 (1.17%)
Volume: 708,743 @07/08/20 4:43:23 PM EDT
Bid Ask Day's Range
44.0 44.19
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
43.35 ? -0.35 (-0.80%)
Volume: 1,650,019 @06/30/20 3:33:29 PM EDT
Bid Ask Day's Range
43.32 43.36 43.04 - 43.46
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhbby $43.9 v -0.82 (-1.83%)
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
42.79 ? 0.25 (0.59%)
Volume: 3,896,833 @06/12/20 4:41:46 PM EDT
Bid Ask Day's Range
42.75 42.98 42.5 - 43.34
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Tamtam Tamtam 4 years ago
Hopefuly
๐Ÿ‘๏ธ0
Golden Cross Golden Cross 4 years ago
Maybe a bottom here
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $42.95 v -0.35 (-0.81%)
๐Ÿ‘๏ธ0
mick mick 4 years ago
Roche Holdings Ltd A (RHHBY)
43.09 ? -1.04 (-2.36%)
Volume: 3,419,409 @05/27/20 4:17:34 PM EDT
Bid Ask Day's Range
43.09 43.14 42.55 - 44.0
RHHBY Detailed Quote
๐Ÿ‘๏ธ0
Taurus69 Taurus69 4 years ago
$rhhby $44.7
๐Ÿ‘๏ธ0
lilcaesarlv lilcaesarlv 5 years ago
Lol they need money for research and POTUS mentions them frequently. Super big company, they own Genetec
My sis was an exec there
Good dividend
Long hold
Set and forget
Peace
๐Ÿ‘๏ธ0